Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Nitric-oxide synthase, brain | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0118 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0118 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0073 | 0.2407 | 0.2407 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.006 | 0.0151 | 0.0151 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0118 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0118 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0118 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0059 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0105 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0118 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0118 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0118 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0118 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0118 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0118 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0118 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0118 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0105 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0118 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0118 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0059 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0073 | 0.2407 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 175 nM | In vitro inhibition of rat neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 175 nM | In vitro inhibition of rat neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 250 nM | In vitro inhibition of human neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 250 nM | In vitro inhibition of human neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 1767 nM | In vitro inhibition of human inducible nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 1767 nM | In vitro inhibition of human inducible nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 3713 nM | In vitro inhibition of human endothelial nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 3713 nM | In vitro inhibition of human endothelial nitric oxide synthase | ChEMBL. | 14998342 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.